APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Drugs Market Analysis and Forecast 2026-2032

22 December 2025218 pages

Choose your research edition.

Industry ResearchCancer Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cancer Drugs include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cancer Drugs sales, projected growth trends, production technology, application and end-user industry.

Cancer Drugs Segment by Company

Takeda

Eisai

Teva

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly

Pfizer

Bayer

Amgen

AbbVie

AstraZeneca

Otsuka

Merck KGaA

Merck & Co.

Ipsen

Gilead Sciences

Celgene

Bristol-Myers Squibb

Biogen Idec

Astellas

Cancer Drugs Segment by Type

Targeted Therapy

Hormonal Therapy (Biologic Therapy)

Chemotherapy

Immunotherapy

Others

Cancer Drugs Segment by Application

Blood Cancer

Gastrointestinal Cancer

Breast Cancer

Prostate Cancer

Respiratory/Lung Cancer

Other Cancers

Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cancer Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Manufacturers Table 3. Hormonal Therapy (Biologic Therapy) Major Manufacturers Table 4. Chemotherapy Major Manufacturers Table 5. Immunotherapy Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Cancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Blood Cancer Major Manufacturers Table 9. Gastrointestinal Cancer Major Manufacturers Table 10. Breast Cancer Major Manufacturers Table 11. Prostate Cancer Major Manufacturers Table 12. Respiratory/Lung Cancer Major Manufacturers Table 13. Other Cancers Major Manufacturers Table 14. Cancer Drugs Industry Trends Table 15. Cancer Drugs Industry Drivers Table 16. Cancer Drugs Industry Opportunities and Challenges Table 17. Cancer Drugs Industry Restraints Table 18. Global Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Cancer Drugs Revenue Market Share by Region (2021-2026) Table 22. Global Cancer Drugs Revenue Market Share by Region (2027-2032) Table 23. Global Cancer Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k tons) Table 24. Global Cancer Drugs Sales by Region (2021-2026) & (k tons) Table 25. Global Cancer Drugs Sales by Region (2027-2032) & (k tons) Table 26. Global Cancer Drugs Sales Market Share by Region (2021-2026) Table 27. Global Cancer Drugs Sales Market Share by Region (2027-2032) Table 28. Global Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Cancer Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Cancer Drugs Sales Market Share by Manufacturers (2021-2026) Table 32. Global Cancer Drugs Sales Price (US$/ton) of Manufacturers (2021-2026) Table 33. Global Cancer Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Cancer Drugs Manufacturers, Product Type & Application Table 36. Global Cancer Drugs Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Cancer Drugs Revenue Market Share by Type (2021-2026) Table 43. Global Cancer Drugs Revenue Market Share by Type (2027-2032) Table 44. Global Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 45. Global Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 46. Global Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 47. Global Cancer Drugs Sales Market Share by Type (2021-2026) Table 48. Global Cancer Drugs Sales Market Share by Type (2027-2032) Table 49. Global Cancer Drugs Price by Type (2021-2026) & (US$/ton) Table 50. Global Cancer Drugs Price by Type (2027-2032) & (US$/ton) Table 51. Global Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 53. Global Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 54. Global Cancer Drugs Revenue Market Share by Application (2021-2026) Table 55. Global Cancer Drugs Revenue Market Share by Application (2027-2032) Table 56. Global Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 57. Global Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 58. Global Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 59. Global Cancer Drugs Sales Market Share by Application (2021-2026) Table 60. Global Cancer Drugs Sales Market Share by Application (2027-2032) Table 61. Global Cancer Drugs Price by Application (2021-2026) & (US$/ton) Table 62. Global Cancer Drugs Price by Application (2027-2032) & (US$/ton) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 66. Takeda Cancer Drugs Product Portfolio Table 67. Takeda Recent Development Table 68. Eisai Company Information Table 69. Eisai Business Overview Table 70. Eisai Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Eisai Cancer Drugs Product Portfolio Table 72. Eisai Recent Development Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Teva Cancer Drugs Product Portfolio Table 77. Teva Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Sanofi Cancer Drugs Product Portfolio Table 82. Sanofi Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Cancer Drugs Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. Novartis Cancer Drugs Product Portfolio Table 92. Novartis Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. Roche Cancer Drugs Product Portfolio Table 97. Roche Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 101. Eli Lilly Cancer Drugs Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 106. Pfizer Cancer Drugs Product Portfolio Table 107. Pfizer Recent Development Table 108. Bayer Company Information Table 109. Bayer Business Overview Table 110. Bayer Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 111. Bayer Cancer Drugs Product Portfolio Table 112. Bayer Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 116. Amgen Cancer Drugs Product Portfolio Table 117. Amgen Recent Development Table 118. AbbVie Company Information Table 119. AbbVie Business Overview Table 120. AbbVie Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 121. AbbVie Cancer Drugs Product Portfolio Table 122. AbbVie Recent Development Table 123. AstraZeneca Company Information Table 124. AstraZeneca Business Overview Table 125. AstraZeneca Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 126. AstraZeneca Cancer Drugs Product Portfolio Table 127. AstraZeneca Recent Development Table 128. Otsuka Company Information Table 129. Otsuka Business Overview Table 130. Otsuka Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 131. Otsuka Cancer Drugs Product Portfolio Table 132. Otsuka Recent Development Table 133. Merck KGaA Company Information Table 134. Merck KGaA Business Overview Table 135. Merck KGaA Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 136. Merck KGaA Cancer Drugs Product Portfolio Table 137. Merck KGaA Recent Development Table 138. Merck & Co. Company Information Table 139. Merck & Co. Business Overview Table 140. Merck & Co. Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 141. Merck & Co. Cancer Drugs Product Portfolio Table 142. Merck & Co. Recent Development Table 143. Ipsen Company Information Table 144. Ipsen Business Overview Table 145. Ipsen Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 146. Ipsen Cancer Drugs Product Portfolio Table 147. Ipsen Recent Development Table 148. Gilead Sciences Company Information Table 149. Gilead Sciences Business Overview Table 150. Gilead Sciences Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 151. Gilead Sciences Cancer Drugs Product Portfolio Table 152. Gilead Sciences Recent Development Table 153. Celgene Company Information Table 154. Celgene Business Overview Table 155. Celgene Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 156. Celgene Cancer Drugs Product Portfolio Table 157. Celgene Recent Development Table 158. Bristol-Myers Squibb Company Information Table 159. Bristol-Myers Squibb Business Overview Table 160. Bristol-Myers Squibb Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 161. Bristol-Myers Squibb Cancer Drugs Product Portfolio Table 162. Bristol-Myers Squibb Recent Development Table 163. Biogen Idec Company Information Table 164. Biogen Idec Business Overview Table 165. Biogen Idec Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 166. Biogen Idec Cancer Drugs Product Portfolio Table 167. Biogen Idec Recent Development Table 168. Astellas Company Information Table 169. Astellas Business Overview Table 170. Astellas Cancer Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 171. Astellas Cancer Drugs Product Portfolio Table 172. Astellas Recent Development Table 173. North America Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 174. North America Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 175. North America Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 176. North America Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 177. North America Cancer Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 178. North America Cancer Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 179. North America Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 180. North America Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 181. North America Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 182. North America Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 183. North America Cancer Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 184. North America Cancer Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 185. North America Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. North America Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. North America Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. North America Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 189. North America Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 190. North America Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 191. North America Cancer Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 192. North America Cancer Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 193. United States Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 194. Canada Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 195. Mexico Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 196. Europe Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 197. Europe Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 198. Europe Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 199. Europe Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 200. Europe Cancer Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 201. Europe Cancer Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 202. Europe Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 203. Europe Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 204. Europe Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 205. Europe Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 206. Europe Cancer Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 207. Europe Cancer Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 208. Europe Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. Europe Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 210. Europe Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 211. Europe Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 212. Europe Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 213. Europe Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 214. Europe Cancer Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 215. Europe Cancer Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 216. Germany Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 217. France Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 218. U.K. Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 219. Italy Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 220. Russia Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 221. Spain Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 222. Netherlands Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 223. Switzerland Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 224. Sweden Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 225. Poland Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 226. China Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 227. China Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 228. China Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 229. China Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 230. China Cancer Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 231. China Cancer Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 232. China Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 233. China Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 234. China Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 235. China Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 236. China Cancer Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 237. China Cancer Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 238. Asia Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 239. Asia Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 240. Asia Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 241. Asia Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 242. Asia Cancer Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 243. Asia Cancer Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 244. Asia Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 245. Asia Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 246. Asia Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 247. Asia Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 248. Asia Cancer Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 249. Asia Cancer Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 250. Asia Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. Asia Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. Asia Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. Asia Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 254. Asia Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 255. Asia Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 256. Asia Cancer Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 257. Asia Cancer Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 258. Japan Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 259. South Korea Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 260. India Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 261. Australia Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 262. Taiwan Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 263. Southeast Asia Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 264. SAMEA Cancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 265. SAMEA Cancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 266. SAMEA Cancer Drugs Sales by Type (2021-2026) & (k tons) Table 267. SAMEA Cancer Drugs Sales by Type (2027-2032) & (k tons) Table 268. SAMEA Cancer Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 269. SAMEA Cancer Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 270. SAMEA Cancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 271. SAMEA Cancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 272. SAMEA Cancer Drugs Sales by Application (2021-2026) & (k tons) Table 273. SAMEA Cancer Drugs Sales by Application (2027-2032) & (k tons) Table 274. SAMEA Cancer Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 275. SAMEA Cancer Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 276. SAMEA Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 277. SAMEA Cancer Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 278. SAMEA Cancer Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 279. SAMEA Cancer Drugs Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 280. SAMEA Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 281. SAMEA Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 282. SAMEA Cancer Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 283. SAMEA Cancer Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 284. Brazil Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 285. Argentina Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 286. Chile Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 287. Colombia Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 288. Peru Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 289. Saudi Arabia Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 290. Israel Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 291. UAE Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 292. Turkey Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 293. Iran Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 294. Egypt Cancer Drugs Revenue (2021-2032) & (US$ Million) Table 295. Key Raw Materials Table 296. Raw Materials Key Suppliers Table 297. Cancer Drugs Distributors List Table 298. Cancer Drugs Customers List Table 299. Research Programs/Design for This Report Table 300. Authors List of This Report Table 301. Secondary Sources Table 302. Primary Sources List of Figures Figure 1. Cancer Drugs Image Figure 2. Global Cancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Hormonal Therapy (Biologic Therapy) Image Figure 6. Chemotherapy Image Figure 7. Immunotherapy Image Figure 8. Others Image Figure 9. Global Cancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Cancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Blood Cancer Image Figure 12. Gastrointestinal Cancer Image Figure 13. Breast Cancer Image Figure 14. Prostate Cancer Image Figure 15. Respiratory/Lung Cancer Image Figure 16. Other Cancers Image Figure 17. Global Cancer Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 19. Global Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Cancer Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Cancer Drugs Revenue Market Share by Region (2021-2032) Figure 22. Global Cancer Drugs Sales (2021-2032) & (k tons) Figure 23. Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 24. Global Cancer Drugs Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico Cancer Drugs Sales YoY (2021-2032) & (k tons) Figure 26. Europe Cancer Drugs Sales YoY (2021-2032) & (k tons) Figure 27. China Cancer Drugs Sales YoY (2021-2032) & (k tons) Figure 28. Asia (Excluding China) Cancer Drugs Sales YoY (2021-2032) & (k tons) Figure 29. South America, Middle East and Africa Cancer Drugs Sales YoY (2021-2032) & (k tons) Figure 30. Global Cancer Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Cancer Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Cancer Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 36. Global Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 37. Global Cancer Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global Cancer Drugs Sales Market Share by Type (2021-2032) Figure 39. Global Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global Cancer Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 42. Global Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 43. Global Cancer Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global Cancer Drugs Sales Market Share by Application (2021-2032) Figure 45. North America Cancer Drugs Revenue Share by Type (2021-2032) Figure 46. North America Cancer Drugs Sales Share by Type (2021-2032) Figure 47. North America Cancer Drugs Revenue Share by Application (2021-2032) Figure 48. North America Cancer Drugs Sales Share by Application (2021-2032) Figure 49. North America Cancer Drugs Revenue Share by Country (2021-2032) Figure 50. North America Cancer Drugs Sales Share by Country (2021-2032) Figure 51. Europe Cancer Drugs Revenue Share by Type (2021-2032) Figure 52. Europe Cancer Drugs Sales Share by Type (2021-2032) Figure 53. Europe Cancer Drugs Revenue Share by Application (2021-2032) Figure 54. Europe Cancer Drugs Sales Share by Application (2021-2032) Figure 55. Europe Cancer Drugs Revenue Share by Country (2021-2032) Figure 56. Europe Cancer Drugs Sales Share by Country (2021-2032) Figure 57. China Cancer Drugs Revenue Share by Type (2021-2032) Figure 58. China Cancer Drugs Sales Share by Type (2021-2032) Figure 59. China Cancer Drugs Revenue Share by Application (2021-2032) Figure 60. China Cancer Drugs Sales Share by Application (2021-2032) Figure 61. Asia Cancer Drugs Revenue Share by Type (2021-2032) Figure 62. Asia Cancer Drugs Sales Share by Type (2021-2032) Figure 63. Asia Cancer Drugs Revenue Share by Application (2021-2032) Figure 64. Asia Cancer Drugs Sales Share by Application (2021-2032) Figure 65. Asia Cancer Drugs Revenue Share by Country (2021-2032) Figure 66. Asia Cancer Drugs Sales Share by Country (2021-2032) Figure 67. SAMEA Cancer Drugs Revenue Share by Type (2021-2032) Figure 68. SAMEA Cancer Drugs Sales Share by Type (2021-2032) Figure 69. SAMEA Cancer Drugs Revenue Share by Application (2021-2032) Figure 70. SAMEA Cancer Drugs Sales Share by Application (2021-2032) Figure 71. SAMEA Cancer Drugs Revenue Share by Country (2021-2032) Figure 72. SAMEA Cancer Drugs Sales Share by Country (2021-2032) Figure 73. Cancer Drugs Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Cancer Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Hormonal Therapy (Biologic Therapy)
  • Chemotherapy
  • Immunotherapy
  • Others
Applications
  • Blood Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Other Cancers
Companies covered
  • Takeda
  • Eisai
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Otsuka
  • Merck KGaA
  • Merck & Co.
  • Ipsen
  • Gilead Sciences
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Drugs Market by Type
  3. 1.2.1 Global Cancer Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Hormonal Therapy (Biologic Therapy)
  6. 1.2.4 Chemotherapy
  7. 1.2.5 Immunotherapy
  8. 1.2.6 Others
  9. 1.3 Cancer Drugs Market by Application
  10. 1.3.1 Global Cancer Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Blood Cancer
  12. 1.3.3 Gastrointestinal Cancer
  13. 1.3.4 Breast Cancer
  14. 1.3.5 Prostate Cancer
  15. 1.3.6 Respiratory/Lung Cancer
  16. 1.3.7 Other Cancers
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Cancer Drugs Market Dynamics
  1. 2.1 Cancer Drugs Industry Trends
  2. 2.2 Cancer Drugs Industry Drivers
  3. 2.3 Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cancer Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cancer Drugs Revenue by Region
  3. 3.2.1 Global Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Cancer Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Cancer Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cancer Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cancer Drugs Sales by Region
  9. 3.4.1 Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cancer Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Cancer Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Cancer Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cancer Drugs Revenue by Manufacturers
  2. 4.1.1 Global Cancer Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cancer Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cancer Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Drugs Sales by Manufacturers
  6. 4.2.1 Global Cancer Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cancer Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cancer Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cancer Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cancer Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cancer Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Cancer Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cancer Drugs Market CR5 and HHI
  16. 4.8.2 2025 Cancer Drugs Tier 1, Tier 2, and Tier 3
5 Cancer Drugs Market by Type
  1. 5.1 Global Cancer Drugs Revenue by Type
  2. 5.1.1 Global Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cancer Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cancer Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cancer Drugs Sales by Type
  6. 5.2.1 Global Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Drugs Sales by Type (2021-2032) & (k tons)
  8. 5.2.3 Global Cancer Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cancer Drugs Price by Type
6 Cancer Drugs Market by Application
  1. 6.1 Global Cancer Drugs Revenue by Application
  2. 6.1.1 Global Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cancer Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cancer Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cancer Drugs Sales by Application
  6. 6.2.1 Global Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cancer Drugs Sales by Application (2021-2032) & (k tons)
  8. 6.2.3 Global Cancer Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cancer Drugs Price by Application
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Cancer Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Eisai
  8. 7.2.1 Eisai Company Information
  9. 7.2.2 Eisai Business Overview
  10. 7.2.3 Eisai Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Cancer Drugs Product Portfolio
  12. 7.2.5 Eisai Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Teva Cancer Drugs Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Cancer Drugs Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Cancer Drugs Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Cancer Drugs Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche Cancer Drugs Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Cancer Drugs Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Cancer Drugs Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Cancer Drugs Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 Amgen
  62. 7.11.1 Amgen Company Information
  63. 7.11.2 Amgen Business Overview
  64. 7.11.3 Amgen Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Cancer Drugs Product Portfolio
  66. 7.11.5 Amgen Recent Developments
  67. 7.12 AbbVie
  68. 7.12.1 AbbVie Company Information
  69. 7.12.2 AbbVie Business Overview
  70. 7.12.3 AbbVie Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 AbbVie Cancer Drugs Product Portfolio
  72. 7.12.5 AbbVie Recent Developments
  73. 7.13 AstraZeneca
  74. 7.13.1 AstraZeneca Company Information
  75. 7.13.2 AstraZeneca Business Overview
  76. 7.13.3 AstraZeneca Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 AstraZeneca Cancer Drugs Product Portfolio
  78. 7.13.5 AstraZeneca Recent Developments
  79. 7.14 Otsuka
  80. 7.14.1 Otsuka Company Information
  81. 7.14.2 Otsuka Business Overview
  82. 7.14.3 Otsuka Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Otsuka Cancer Drugs Product Portfolio
  84. 7.14.5 Otsuka Recent Developments
  85. 7.15 Merck KGaA
  86. 7.15.1 Merck KGaA Company Information
  87. 7.15.2 Merck KGaA Business Overview
  88. 7.15.3 Merck KGaA Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Merck KGaA Cancer Drugs Product Portfolio
  90. 7.15.5 Merck KGaA Recent Developments
  91. 7.16 Merck & Co.
  92. 7.16.1 Merck & Co. Company Information
  93. 7.16.2 Merck & Co. Business Overview
  94. 7.16.3 Merck & Co. Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Merck & Co. Cancer Drugs Product Portfolio
  96. 7.16.5 Merck & Co. Recent Developments
  97. 7.17 Ipsen
  98. 7.17.1 Ipsen Company Information
  99. 7.17.2 Ipsen Business Overview
  100. 7.17.3 Ipsen Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Ipsen Cancer Drugs Product Portfolio
  102. 7.17.5 Ipsen Recent Developments
  103. 7.18 Gilead Sciences
  104. 7.18.1 Gilead Sciences Company Information
  105. 7.18.2 Gilead Sciences Business Overview
  106. 7.18.3 Gilead Sciences Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Gilead Sciences Cancer Drugs Product Portfolio
  108. 7.18.5 Gilead Sciences Recent Developments
  109. 7.19 Celgene
  110. 7.19.1 Celgene Company Information
  111. 7.19.2 Celgene Business Overview
  112. 7.19.3 Celgene Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Celgene Cancer Drugs Product Portfolio
  114. 7.19.5 Celgene Recent Developments
  115. 7.20 Bristol-Myers Squibb
  116. 7.20.1 Bristol-Myers Squibb Company Information
  117. 7.20.2 Bristol-Myers Squibb Business Overview
  118. 7.20.3 Bristol-Myers Squibb Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Bristol-Myers Squibb Cancer Drugs Product Portfolio
  120. 7.20.5 Bristol-Myers Squibb Recent Developments
  121. 7.21 Biogen Idec
  122. 7.21.1 Biogen Idec Company Information
  123. 7.21.2 Biogen Idec Business Overview
  124. 7.21.3 Biogen Idec Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Biogen Idec Cancer Drugs Product Portfolio
  126. 7.21.5 Biogen Idec Recent Developments
  127. 7.22 Astellas
  128. 7.22.1 Astellas Company Information
  129. 7.22.2 Astellas Business Overview
  130. 7.22.3 Astellas Cancer Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Astellas Cancer Drugs Product Portfolio
  132. 7.22.5 Astellas Recent Developments
8 North America
  1. 8.1 North America Cancer Drugs Market Size by Type
  2. 8.1.1 North America Cancer Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Cancer Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Cancer Drugs Price by Type (2021-2032)
  5. 8.2 North America Cancer Drugs Market Size by Application
  6. 8.2.1 North America Cancer Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Cancer Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Cancer Drugs Price by Application (2021-2032)
  9. 8.3 North America Cancer Drugs Market Size by Country
  10. 8.3.1 North America Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cancer Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Drugs Market Size by Type
  2. 9.1.1 Europe Cancer Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cancer Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Cancer Drugs Price by Type (2021-2032)
  5. 9.2 Europe Cancer Drugs Market Size by Application
  6. 9.2.1 Europe Cancer Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cancer Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Cancer Drugs Price by Application (2021-2032)
  9. 9.3 Europe Cancer Drugs Market Size by Country
  10. 9.3.1 Europe Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cancer Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Cancer Drugs Market Size by Type
  2. 10.1.1 China Cancer Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Cancer Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Cancer Drugs Price by Type (2021-2032)
  5. 10.2 China Cancer Drugs Market Size by Application
  6. 10.2.1 China Cancer Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Cancer Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Cancer Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Drugs Market Size by Type
  2. 11.1.1 Asia Cancer Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cancer Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Cancer Drugs Price by Type (2021-2032)
  5. 11.2 Asia Cancer Drugs Market Size by Application
  6. 11.2.1 Asia Cancer Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cancer Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Cancer Drugs Price by Application (2021-2032)
  9. 11.3 Asia Cancer Drugs Market Size by Country
  10. 11.3.1 Asia Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cancer Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Drugs Market Size by Type
  2. 12.1.1 SAMEA Cancer Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cancer Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cancer Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Cancer Drugs Market Size by Application
  6. 12.2.1 SAMEA Cancer Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cancer Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cancer Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Cancer Drugs Market Size by Country
  10. 12.3.1 SAMEA Cancer Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cancer Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cancer Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cancer Drugs Value Chain Analysis
  2. 13.1.1 Cancer Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cancer Drugs Production Mode & Process
  6. 13.2 Cancer Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cancer Drugs Distributors
  9. 13.2.3 Cancer Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst